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In chronic obstructive pulmonary disease (COPD) which consists of emphysema and chronic bronchitis, alveolar 
tissue and/or bronchiolar walls are progressively destroyed. This suggests cell death by necrosis and/or apoptosis 
although no direct evidence of apoptosis has been reported. It was speculated that the apoptosis-related factors are 
associated with the progression of COPD. Fas/Apo-1 receptor (Fas), Fas ligand (Fas-L) and soluble Fas ligand 
(sFas-L) are inducers, while soluble Fas (sFas) is an inhibitor of apoptosis. In this study, plasma sFas and sFas-L 
were measured in 19 COPD patients receiving supplemental 0, (severe COPD) and 20 COPD patients not receiving 
supplemental 0, (mild/moderate COPD). Twenty-two age- and sex-matched healthy volunteers (healthy controls) 
and 20 patients receiving supplemental 0, and with levels of hypoxaemia similar to severe COPD due to other 
pulmonary diseases (disease controls) were also examined. Plasma sFas-L was within normal limits in all groups. 
Plasma sFas levels were similar among healthy controls, disease controls, and mild/moderate COPD patients, but 
significantly increased in severe COPD (2.6 l 1.1, 2.6 i 0.2, 2.8 & 0.2 and 4.8 * 1 .O ng ml - ‘, respectively). Although 
PaO, was lower in severe COPD than in mild/moderate COPD, and PaCO, was higher in severe COPD than in 
mild/moderate COPD, they were close between severe COPD and disease controls. Tumour necrosis factor-a 
(TNF-a), interleukin 6 (IL-6) and C-reactive protein (CRP) were increased in patients with COPD, but were similar 
in both severe and mild/moderate COPD patients. We conclude that increased plasma sFas, which is independent of 
hypoxaemia, and increases in PaCO,, TNF-a, IL-6 and inflammation, may be associated with progression of COPD. 
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Introduction 
Apoptosis differs from necrosis in terms of ultrastructural 
and biochemical features that include cytoplasmic and 
nuclear condensation, subsequent formation of membrane- 
bound apoptotic bodies (segmentation of the nucleus), and 
extensive degeneration of chromosomal DNA into oligo- 
mers of about 180 bp caused by activation of endogenous 
endonuclease (1). Apoptosis is not characteristically associ- 
ated with inflammatory cell infiltration, unlike necrosis. 
Recent evidence suggests that apoptosis contributes to the 
pathophysiology of cancer, [including lung cancer (2,3)], 
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viral infections, autoimmune diseases, and neurodegenera- 
tive disorders (4). Tsuyuki et al. showed that activation of 
the Fas/Apo-I receptor (Fas) on lung eosinophils induces 
apoptosis and reduces eosinophilic inflammation of airways 
(5). Chronic obstructive pulmonary disease (COPD) is 
defined as a disease state characterized by the presence of 
airflow obstruction due to chronic bronchitis or emphy- 
sema, the two usually occurring together (6). At present, 
there is no direct evidence that apoptosis occurs in the lungs 
of patients with COPD. However, it is well-known that a 
turnover is observed in alveolar cells or bronchial cells in 
the physiological state (7,8). COPD is a destructive disease 
of the lungs and causes progressive loss of alveoli and/or 
bronchioles (9-l 1). These findings suggest that cell death in 
alveoli and/or bronchioles may occur during COPD and 
may be at least in part due to apoptosis. 
To date, several inducers and inhibitors of apoptosis 
have been reported. The Fas-Fas ligand (Fas-L) system is a 
potential inducer of apoptosis. Fas (designated as CD9.5) is 
a cell surface protein consisting of 319 amino acids with a 
single transmembrane domain, and belongs to the nerve 
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growth factor receptor - tumour necrosis factor (TNF) 
receptor family (type I membrane protein) (12-l 5). Molecu- 
lar cloning and nucleotide sequence analysis have revealed 
a human Fas mRNA variant that encodes a soluble Fas 
(sFas) molecule lacking the transmembrane domain 
because of a deletion of the exon encoding this region. sFas 
is found in culture supernatants of human B- and T-cell 
lines. Fas-L is a type II membrane protein that belongs 
to the TNF family (16). The membrane-bound human 
Fas-L is converted to soluble form (sFas-L) by matrix 
metalloproteinase-like enzyme (17). Human sFas-L, a 
26 kDa glycoprotein, consists of the extracellular region of 
Fas-L. In mice, Fas-L is predominantly expressed in acti- 
vated T cells, whereas Fas is expressed in various tissues 
including the thymus, heart, lungs, liver, and ovaries but 
not in the brain or spleen (15,18). Binding of Fas-L, sFas-L 
or agonistic anti-Fas antibody to Fas induces apoptosis 
(16,18,19). However, sFas blocks apoptosis, by inhibiting 
binding between Fas and Fas-L or sFas-L on the cell 
membrane. Serum sFas levels have been reported to be 
elevated in patients with systemic lupus erythematosus and 
B- and T-cell leukaemias, as are serum sFas-L levels in 
patients with large granular lymphocytic leukaemia and 
natural killer cell lymphoma (20-22). However, whether 
plasma levels of sFas and sFas-L are elevated or not in 
patients with COPD remains to be elucidated. In addition, 
TNF-a, the cytolytic activity of which is mediated by Fas, 
and interleukin 6 (IL-6), a cytokine inducing transcription 
of Fas gene, are Fas-Fas-L system related factors 
(16,23,24), and TNF-a, and C-reactive protein (CRP) are 
increased in the plasma of patients with COPD (25,26). 
Therefore, the present study assessed (1) whether the 
plasma concentrations of sFas-L, an inducer of apoptosis, 
and sFas, an inhibitor of apoptosis, are increased in mild, 
moderate, or severe COPD patients; and (2) whether the 
concentrations of these proteins are related to other clinical 
parameters, such as blood gas analysis, pulmonary function 
test, and CRP, TNF-a, or IL-6. 
Methods 
SUBJECTS 
Thirty-nine patients with COPD diagnosed by history, 
physical examination, roentgenographic examination and 
pulmonary function tests, according to the Guidelines of 
the American Thoracic Society (6), were included in the 
present study. The following criteria were used for patient 
selection: 1, clinically stable condition; 2, no recent change 
of drugs; 3, normal left ventricular ejection fraction 
(LVEF) in echocardiography (LVEF ~0.55); 4, normal 
plasma creatinine concentration; and 5, absence of other 
pathological conditions (e.g. bronchial asthma, cancer, 
tuberculosis, neurodegenerative disorder, viral infection, 
liver disease, cardiac disease, collagen disease, sarcoidosis, 
and diabetes mellitus). The 39 patients with COPD were 
classified into 19 patients receiving supplemental 0, 
(severe COPD) and 20 patients no receiving supplemental 
0, (mild/moderate COPD). Age and sex (male/female) 
were similar in severe COPD (66 * 2, 13/6) and mild/ 
moderate COPD (66 f 3, 14/6). The controls (22 in total) 
were healthy age- and sex-matched volunteers without any 
disease. In addition, 20 age- and sex-matched patients 
receiving supplemental 0, and with levels of hypoxaemia 
similar to severe COPD including 12 with old tubercu- 
losis, six with idiopathic pulmonary fibrosis, and two with 
pneumoconiosis were used as disease controls. Supple- 
mental 0, was given to the severe COPD and disease 
control patients with PaO, levels below 55 mmHg at rest 
during hospitalization. Healthy and disease controls were 
not matched on smoking history. Bronchodilator agents 
including beta-agonists, anticholinergic agents and theo- 
phylline, antitussives, and expectorants were administered 
in COPD patients. However, there were no significant 
differences in these drugs between severe and mild/ 
moderate COPD patients and disease controls. Informed 
consent was obtained from all subjects. The study was 
approved by the Research and Ethics Committee of Gifu 
University. 
BLOOD SAMPLING 
Peripheral venous blood samples were taken slowly from 
an antecubital vein, and transferred to chilled disposable 
tubes containing 2 sodium-ethylenediamine tetraacetic acid 
(1.5 mg ml - ‘). Then, the disposable tubes were promptly 
centrifuged at 4°C and aliquots of plasma immediately 
stored at - 80°C until analysis for plasma levels of sFas, 
sFas-L, and the cytokines. 
Arterial blood gas samples were taken from a femoral 
artery and were transferred to chilled disposable tubes 
containing heparin, and pH, PaCO,, and PaO, levels were 
measured. 
SFAS AND SFAS-L LEVELS BY ELISA 
We have developed a highly sensitive enzyme-linked 
immunosorbent assay (ELISA) for sFas in plasma (27). 
Polystyrene plates were precoated with rabbit IgG for 
anti-human Fas synthetic peptide. The detection limit was 
0.01 ng ml-‘. The average within-run and between-run 
coefficients of variation were 3.4% and 5.7%, respectively. 
The recovery of added sFas to serum ranged from 93% to 
118%. 
Plasma sFas-L was also quantitated by sandwich ELISA 
using NOK-1 (mouse IgGl, k) and NOK-3 (mouse IgM, k), 
monoclonal antibodies purified from mice immunized by 
intraperitoneal injection of human Fas-L (mouse T lym- 
phoma cell lines) (28). Serial dilution of purified sFas-L, 
which was affinity purified from human Fas-L supernatant 
on a NOK-1 column, was used as the standard. The 
detection limit of this assay was 0.2 ng ml - ’ 
For eight patients with COPD, a second plasma sampling 
for the measurement of the reproducibilities of plasma sFas 
and sFas-L levels was performed 1 day after the first plasma 
sampling. The reproducibilities of the assay of sFas and 
sFas-L for the same plasma and paired samples taken at 
intervals of 1 day by this method were 3.4 * 3.9% and 
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TABLE 1. Patient characteristics 

















Never smoked (%) 
Formerly smoked (%) 
Current smoker (%) 




VC (% pred) 
FEV,/FVC (%) 
CRPt (mg dl ~ ‘) 
19 20 20 22 
1316 1416 14/6 1517 
66 + 2 66k 3 67k 3 66dc 1 
0 6 0 22 
0 6 3 0 
7 2 4 0 
5 6 6 0 
7 0 7 0 
1 (5) 1 (5) 11 (55) 9 (41) 
11 (58) 10 (50) 6 (30) 6 (27) 
7 (37) 9 (45) 3 (15) 7 (32) 
1109 f 123*,** 1045 & 201*,** 588 f 151 587 31129 
7.372 +c 0.016 7.395 Lt 0.010 7.374 * 0.019 7.401 zk 0.005 
48.4 f 1.8*%*** 42.2 z!z 2.8** 49.4 * 2.2* 38.0 f 0.8 
51.7 + 0.9,*** 76.3 f 2.4*,** 51.3 zt 1.1* 86.9 f 0.9 
[65.2 f 2.31 [65.9 zt 2.81 
70.5 f 2.6*.**,*** 81.9 zk 3.3*,** 46.2 zk 3.0* 92.6 f 0.8 
42.0 f 2.3*,** 48.0 f 1.9**** 75.9 f 4.0* 88.9 it 1.1 
2.33 zt 0.52* 1.52 zk 0.24* 2.41 zk 0.59 0.09 f 0.06 
Values are expressed as means f SEM. pH, PaCO,, and PaO, are the data before patients received supplemental 0,. [ 1, The 
data after patients received supplemental 0,. t, C-reactive protein. 
*P<O.O5 vs healthy control; **P<O.O5 vs disease control; ***P<O.O5, vs mild/moderate COPD. 
4.9 & 2.9%, 7.0 f 2.2% and 4.3 * 2.0%, respectively. These 
results were satisfactorily small and reliable. 
MEASUREMENTS OF PLASMA LEVELS OF 
TNF-a, IL-6, AND CRP 
The plasma level of TNF-a was measured using a sandwich 
ELISA kit with two monoclonal anti-human TNF-a anti- 
bodies (No. 1121, IMMUNOTECH, Marseille, France). 
The plasma level of IL-6 was also measured using a 
two-step sandwich ELISA kit with two monoclonal anti- 
human IL-6 antibodies and rIL-6 standards (Human B-6 
ELISA Kit Fujirebio, Fujirebio Inc., Japan). The normal 
plasma level of IL-6 is less than 3 pg ml - ‘. CRP was 
measured by latex nephelometric immunoassay with a 
detection limit of 0.03 mg dl ~ i. 
STATISTICAL METHODS 
Statistical analysis was performed on the data obtained 
from the 81 subjects. Plasma levels of sFas, sFas-L, and the 
cytokines, and the parameters obtained from blood gas 
analysis and pulmonary function test were compared 
among groups using one-way analysis of variance 
(ANOVA) (Bonferroni!Dunn). This method is recom- 
mended for general use since it is easier to apply, has a 
wider range of applications, and gives lower critical values 
than other procedures (29). If the difference was significant, 
a modified unpaired t-test was used. Correlations of the 
plasma levels of sFas and sFas-L with cytokines were 
examined using simple linear regression analysis by the 
least-squares method. 
All values are expressed as the mean ZIZ standard error of 
the mean (SEM). A P value of less than 0.05 was regarded as 
significant. 
Results 
PATIENT CHARACTERISTICS AND BLOOD GAS 
OR PULMONARY FUNCTIONAL DATA 
The characteristics of the patients are summarized in 
Table 1. There were no significant differences in age and 
gender among severe COPD, mild/moderate COPD, and 
the healthy and disease controls. Brinkman smoking index 
was significantly higher in severe and mild/moderate COPD 
patients than in healthy and disease controls. The percent- 
age of smokers was also significantly higher in severe and 
mild/moderate COPD groups than in the two control 
groups. However, there were no significant differences 
between severe and mild/moderate COPD patients. There 
were no significant differences in the age at which smoking 
started among the four groups. The PaCO, concentra- 
tion was significantly higher in severe COPD and disease 
996 N. YASUDA ET AL. 
TABLE 2. Plasma concentrations of sFas, sFas-L, TNF-a, and IL-6 







sFas (ng ml - ‘) 4.8 * 1.0*,**.*** 2.8 i 0.2 2.6 + 0.2 2.6 h 0.1 
sFas-L (ng ml - ‘) 0.58 f 0.01 0.55 zt 0.02 0.54 f 0.02 0.56 zt 0.02 
TNF-a (pg ml - ‘) 23.2 f 8.4*,** 20.6 ct 6.9*,** 9.4 f 2.7 3.9 f 0.5 
IL-6 (pg ml ~ ‘) 13.9 f 2.2* 16.5 f 5.4* 15.4 f 5.2* 2.1 * 0.3 
Values are means f stx 
*P<O.O5 vs healthy control; **P<O.O5 vs disease control; ***P<O.O5 vs mild/moderate COPD. 
controls than in mild/moderate COPD and healthy con- 
trols. PaO, was significantly lower in severe COPD and 
disease controls than in mild/moderate COPD. This value 
was also significantly lower in mild/moderate COPD than in 
the healthy controls. However, PaO,, PaCO,, and pH were 
similar between severe COPD and disease controls. VC 
(vital capacity) was decreased markedly in disease controls 
and slightly in severe and mild/moderate COPD. FEV,/ 
FVC was decreased markedly in severe and mild/moderate 
COPD and slightly in disease controls. The amount of CRP 
was significantly higher in severe and mild/moderate COPD 
patients and disease controls than in healthy controls. 
However, there was no significant difference among severe 
COPD, mild/moderate COPD, and disease controls. 
Discussion 
The serum level of sFas-L was 0.56 * 0.02 ng ml - ’ in 
healthy controls. There was no evidence of an increase in 
sFas-L levels in patients with COPD. 
The plasma sFas level for a group of 155 healthy subjects 
was 2.3 -+ 0.6 ng ml- ‘, and was higher in males than 
females and increased with age (27), but was similar to the 
present data in the healthy subjects. However, the plasma 
PLASMA LEVELS OF SFAS AND SFAS-L 14 c . (20.4) 
Plasma levels of sFas-L were similar among the four groups 
(Table 2). Plasma levels of sFas were significantly increased 
in severe COPD, compared to mild/moderate COPD and the 
healthy controls and disease controls. There was no signifi- 
cant difference among mild/moderate COPD, the healthy 
controls, and disease controls (Table 2, Fig. 1). The plasma 
levels of sFas in the Grade V patients (the Hugh-Jones 
classification) (30) were increased significantly in COPD 
patients (Fig. 2), but not in disease control (Grade V: 
3.2 & 0.2 ng ml ~ ‘). There was also no significant difference 
in sFas levels between patients with low CRP (CRP< 1.0 mg 
dll ‘) and high CRP (CRP> 1.0 mg dl~ ‘) (Fig. 3). 
12t 
PLASMA LEVELS OF TNF-a AND IL-6 
Although plasma TNF-a concentrations increased in both 
severe COPD and mild/moderate COPD, compared to the 
healthy and disease controls, there was no significant dif- 
ference between the two COPD groups. Plasma IL-6 con- 
centrations increased in severe and mild/moderate COPD, 
and disease controls, compared to the healthy controls, 
however, there was no significant difference among severe 
and mild/moderate COPD, and disease controls (Table 2). 
In severe and mild/moderate COPD patients, neither 
TNF-a nor IL-6 correlated with sFAS levels. Plasma IL-6 
concentrations were significantly higher in the high CRP 
group than in the low CRP group, in severe and mild/ 
moderate COPD patients (Fig. 3). 
0’ 
Healthy Disease Mild/moderate Severe 
control control COPD COPD 
FIG. 1. Comparison of plasma levels of soluble Fas 
among four groups. A group of chronic obstructive pul- 
monary disease patients receiving supplemental 0, (severe 
COPD): II = 19; male/female = 13/6, age = 66 f 2 years. A 
group of chronic obstructive pulmonary disease patients 
not receiving supplemental 0, (mild or moderate COPD; 
mild/moderate COPD): n = 20; male/female = 1416, 
age=66 f 3 years. A group consisting old tuberculosis, 
idiopathic pulmonary fibrosis and pneumoconiosis as dis- 
ease controls receiving supplemental 0, (disease control): 
n =20; male/female= 14/6, age= 67 + 3 years. Healthy con- 
trol group: n=22; male/female= 15/7, age=66 i 1 years. 
Values are means f SEM. *P<O.O5. 
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sFas levels were much lower than those of a previous study 
by Cheng et al. (below 30 ng ml ~ ‘) (20), although the rate 
of elevation in severe COPD patients (approximately two- 
fold) was similar to that in patients with systemic lupus 
erhythematosus, B- and T-cell leukaemias and lymphoma 
reported by them (20,21). Although the reason for this 
difference is unknown, there may be differences in the 
standard and the specificity of antibody to sFas used. In 
addition their study was of a small scale (n=lO), and they 
did not define sex or age differences in healthy subjects. 
Plasma sFas levels were not increased in mild/moderate 
COPD and disease controls, but were in severe COPD. 
PaO, and PaCO, were similar between severe COPD and 
disease controls. Of the patients with Grade V in the 
Hugh-Jones classification (30), the degree of dyspnoea, 
which is related with pulmonary function despite large 
variations within each degree (31-33) plasma sFas was 
increased in COPD patients, but not in disease controls. No 
relationship between plasma sFas and CRP, an indicator of 
inflammation, was seen. It is well-known that Fas mRNA is 
IL-6 dependent in the KT-3 cell line; IL-6 is a potent 
mediator of inflammation (34). Wada et al. reported that 
the nuclear factor needed for IL-6 expression is also an 
inducer of Fas mRNA in influenza virus-infected Hela cells 
of human (23). However, plasma IL-6 levels were similar 
among severe COPD, mild/moderate COPD, and disease 
controls, although significantly elevated relative to healthy 
controls. These findings suggest that (1) plasma sFas is an 
indicator of severity of COPD; and (2) the increase of 
”  
Healthy I II III IV V 
control 
Hugh-Jones 
FIG. 2. Comparison of plasma levels of soluble Fas 
among five grades (the Hugh-Jones classification) of 
chronic obstructive pulmonary disease. I: n=6, male/ 
female= 5/l, age= 70 * 3 years. II: n = 6, male/female = 313, 
age=62 f 7 years. III: n=9, male/female=S/l, age=66 f 3 
years. IV: n= 11, male/female=8/3, age=64 f 4 years. V: 
n=7, male/female=3/4, age=68 * 3 years. Values are 






























Healthy Low CRP High CRP Low CRP High CRP Healthy Low CRP High CRP Low CRP High CRP 
eontml 
Healthy Low CRP High CRP Law CRP High CRP 
Mildhcderate SWWS control Mild/moderate .!GWlT eontro1 Mild/moderate Severe 
COPD COPD COPD COPD COPD COPD 
FIG. 3. Comparison of plasma levels of soluble Fas (sFas) (a), tumour necrosis factor-u (TNF-a); (b), and interleukin-6 
(IL-6) (c) between low and high C-reactive protein (CRP) groups (low CRP; CRP< 1.0 mg dl - ‘, high CRP; CRP 2 
1.0 mg dl - ‘). *P<O.OS. 
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plasma sFas is not due to hypoxaemia, decrease of VC and 
FEV,/FVC, inflammation or an increase of plasma IL-6. 
Plasma sFas levels in severe COPD patients receiving 
supplemental 0, and with Hugh-Jones Grade V varied 
from normal to very high. Significant elevation of the 
plasma sFas level over two standard deviations was seen 
in eight of 19 severe COPD patients and four of seven 
COPD patients with Hugh-Jones Grade V. The mech- 
anism of the variability remains unknown. However, 
plasma sFas may be related to the pathophysiology of the 
progression of COPD, at least, in patients with high 
plasma levels. 
Abnormality of various apoptosis-related factors has 
been reported in patients with COPD. Levels of cytokines 
such as plasma TNF-a, an inducer of apoptosis, are 
elevated in COPD (25). The cytolytic activity of TNF is 
mediated by Fas in animal models (24). Fas and Fas-L 
exhibited homology with TNF receptor and TNF, respect- 
ively. Fas is abundantly expressed in activated lymphocytes 
and in the primary cells from various organs, including the 
lungs. The activation of Fas induces apoptosis of inflam- 
matory cells. Recently, studies using bronchial biopsies in 
patients with COPD have shown an increased number of 
CD3+ (35). In another study, the authors found that more 
severely ill COPD patients had higher concentrations of T 
lymphocytes, suggesting that the latter are related to the 
bronchial hyperreactivity found in some COPD patients 
(35). In the present study, we found that plasma sFas levels 
were increased approximately two-fold in severe COPD 
patients. The elevation of plasma sFas was similar to that in 
patients with systemic lupus erythematosus, B- and T-cell 
leukaemias and lymphoma by Cheng et al. (20). In 
addition, these investigators described that sFas when 
injected at approximately two-fold the control level in 
mice exhibited activity in vivo and inhibited apoptosis, by 
inhibiting the binding of Fas-L or sFas-L to Fas on the cell 
membrane (20). Therefore, the increased plasma sFas in 
severe COPD patients may have an inhibiting effect on 
apoptosis of the infiltrated T lymphocytes in the lungs of 
patients with COPD, although plasma sFas-L, an inducer 
of apoptosis, was not increased in the present study. There 
has been no report on direct evidence that apoptosis, Fas 
and Fas-L in lungs were increased in COPD patients. 
Further investigation on the cytotoxic properties of 
lymphocytes and the identification, localization and 
quantitation of cellular death in lungs is warranted. 
We conclude that elevation of plasma sFas may play 
an important role in the pathophysiology of COPD 
progression. 
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